Alkaptonuria: Current Perspectives

References

• Garrod AE. Croonian lectures on inborn errors of metabolism, lecture II: alkaptonuria. Lancet. 1908;2:73–79.
   Google Scholar
• Fernández-Cañón JM, Granadino B, Beltrán-valero de Bernabé D, et al. The molecular basis of alkaptonuria. Nat Genet. 1996;14(1):19–24. doi:10.1038/ng0996-19
   PubMed Web of Science ®Google Scholar
• La Du BN, Zannoni VG, Laster L, Seegmiller JE. The nature of the defect in tyrosine metabolism in alcaptonuria. J Biol Chem. 1958;230(1):251–260.
   PubMed Web of Science ®Google Scholar
• Zannoni VG, Lomtevas N, Goldfinger S. Oxidation of homogentisic acid to ochronotic pigment in connective tissue. Biochim Biophys Acta. 1969;177(1):94–105. doi:10.1016/0304-4165(69)90068-3
   Web of Science ®Google Scholar
• Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria (invited review; best practice article). J Clin Pathol. 2013;66(5):367–373. doi:10.1136/jclinpath-2012-200877
   PubMed Web of Science ®Google Scholar
• Ranganath LR, Khedr M, Milan AM, et al. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. Mol Genet Metab. 2018;125(1–2):127–134. doi:10.1016/j.ymgme.2018.07.011
   PubMed Web of Science ®Google Scholar
• Ranganath LR, Milan AM, Hughes AT, et al. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Ann Rheum Dis. 2016;75(2):362–367. doi:10.1136/annrheumdis-2014-206033
   PubMed Web of Science ®Google Scholar
• Olsson B, Cox TF, Psarelli EE, et al. Relationship between serum concentrations of nitisinone and its effect on homogentisic acid and tyrosine in patients with alkaptonuria. JIMD Rep. 2015;24:21–27.
   Google Scholar
• Hughes AT, Milan AM, Davison AS, et al. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry. Ann Clin Biochem. 2015;52(Pt 5):597–605. doi:10.1177/0004563215571969
   PubMed Web of Science ®Google Scholar
• Hughes AT, Milan AM, Christensen P, et al. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;963:106–112. doi:10.1016/j.jchromb.2014.06.002
   PubMed Web of Science ®Google Scholar
• Hughes JH, Wilson PJM, Sutherland H, et al. Dietary restriction of tyrosine and phenylalanine lowers tyrosinaemia associated with nitisinone therapy of alkaptonuria. J Inherit Metab Dis. 2019. doi:10.1002/jimd.12172
   Web of Science ®Google Scholar
• Cox TF, Psarelli EE, Taylor S, et al. Subclinical Ochronosis Features In Alkaptonuria: a Cross-Sectional Study. BMJ Innovations. 2019. doi:10.1136/bmjinnov-2018-000324
   Google Scholar
• Al-Sbou M, Mwafi N. Nine cases of Alkaptonuria in one family in southern Jordan. Rheumatol Int. 2012;32(3):621–625. doi:10.1007/s00296-010-1701-1
   Web of Science ®Google Scholar
• Janocha S, Wolz W, Srsen S, et al. The human gene for alkaptonuria (AKU) maps to chromosome 3q. Genomics. 1994;19(1):5–8. doi:10.1006/geno.1994.1003
   Web of Science ®Google Scholar
• Sakthivel S, Zatkova A, Nemethova M, Surovy M, Kadasi L, Saravanan MP. Mutation screening of the HGD gene identifies a novel alkaptonuria mutation with significant founder effect and high prevalence. Ann Hum Genet. 2014;78(3):155–164. doi:10.1111/ahg.12055
   Web of Science ®Google Scholar
• Srsen S, Varga F. Screening for alkaptonuria in the newborn in Slovakia. Lancet. 1978;2(8089):576. doi:10.1016/S0140-6736(78)92910-0
   Web of Science ®Google Scholar
• Pollak MR, Chou YH, Cerda JJ, et al. Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2. Nat Genet. 1993;5(2):201–204. doi:10.1038/ng1093-201
   Web of Science ®Google Scholar
• Fernández-Cañón JM, Peñalva MA. Molecular characterization of a gene encoding a homogentisate dioxygenase from Aspergillus nidulans and identification of its human and plant homologues. J Biol Chem. 1995;270(36):21199–21205. doi:10.1074/jbc.270.36.21199
   Web of Science ®Google Scholar
• Granadino B, Beltrán-valero de Bernabé D, Fernández-Cañón JM, Peñalva MA, Rodríguez de Córdoba S. The human homogentisate 1,2-dioxygenase (HGO) gene. Genomics. 1997;43(2):115–122. doi:10.1006/geno.1997.4805
   Web of Science ®Google Scholar
• Ascher DB, Spiga O, Sekelska M, et al. Homogentisate 1,2-dioxygenase (HGD) gene variants, their analysis and genotype-phenotype correlations in the largest cohort of patients with AKU. Eur J Hum Genet. 2019;27(6):888–902. doi:10.1038/s41431-019-0354-0
   Web of Science ®Google Scholar
• Zatkova A, Sedlackova T, Radvansky J, et al. Identification of 11 novel homogentisate 1,2 dioxygenase variants in alkaptonuria patients and establishment of a novel LOVD-based HGD mutation database. JIMD Rep. 2012;4:55–65.
   PubMedGoogle Scholar
• Spiga O, Cicaloni V, Bernini A, Zatkova A, Santucci A. ApreciseKUre: an approach of precision medicine in a rare disease. BMC Med Inform Decis Mak. 2017;17(1):42. doi:10.1186/s12911-017-0438-0
   Web of Science ®Google Scholar
• Laschi M, Tinti L, Braconi D, et al. Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: implications in alkaptonuria. J Cell Physiol. 2012;227(9):3254–3257. doi:10.1002/jcp.24018
   Web of Science ®Google Scholar
• Bernardini G, Laschi M, Geminiani M, et al. Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria. J Inherit Metab Dis. 2015;38(5):807–814. doi:10.1007/s10545-015-9829-5
   Web of Science ®Google Scholar
• Hughes JH, Liu K, Plagge A, et al. Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase 1 activity is essential in reducing circulating homogentisic acid and for effective therapy 2 in the genetic disease alkaptonuria. Hum Mol Genet. 2019. doi:10.1093/hmg/ddz234
   Web of Science ®Google Scholar
• Titus GP, Mueller HA, Burgner J, Rodríguez de Córdoba S, Peñalva MA, Timm DE. Crystal structure of human homogentisate dioxygenase. Nat Struct Biol. 2000;7(7):542–546. doi:10.1038/76756
   Google Scholar
• Nemethova M, Radvanszky J, Kadasi L, et al. Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on ‘black bone disease’ in Italy. Eur J Hum Genet. 2016;24(1):66–72. doi:10.1038/ejhg.2015.60
   PubMed Web of Science ®Google Scholar
• Zatkova A. An update on molecular genetics of Alkaptonuria (AKU). J Inherit Metab Dis. 2011;34(6):1127–1136. doi:10.1007/s10545-011-9363-z
   Web of Science ®Google Scholar
• Gupta V, Kalaiarasan P, Faheem M, Singh N, Iqbal MA, Bamezai RN. Dominant negative mutations affect oligomerization of human pyruvate kinase M2 isozyme and promote cellular growth and polyploidy. J Biol Chem. 2010;285(22):16864–16873. doi:10.1074/jbc.M109.065029
   Web of Science ®Google Scholar
• Bernini A, Galderisi S, Spiga O, et al. Toward a generalized computational workflow for exploiting transient pockets as new targets for small molecule stabilizers: application to the homogentisate 1,2-dioxygenase mutants at the base of rare disease Alkaptonuria. Comput Biol Chem. 2017;70:133–141. doi:10.1016/j.compbiolchem.2017.08.008
   Web of Science ®Google Scholar
• Rodriguez JM, Timm DE, Titus GP, et al. Structural and functional analysis of mutations in alkaptonuria. Hum Mol Genet. 2000;9(15):2341–2350. doi:10.1093/oxfordjournals.hmg.a018927
   Web of Science ®Google Scholar
• Langford B, Besford M, Hall A, et al. Alkaptonuria severity score index revisited: analysing the AKUSSI and its subcomponent features. JIMD Rep. 2018;41:53–62.
   PubMedGoogle Scholar
• Montagutelli X, Lalouette A, Coude M, Kamoun P, Forest M, Guenet JL. aku, a mutation of the mouse homologous to human alkaptonuria, maps to chromosome 16. Genomics. 1994;19(1):9–11. doi:10.1006/geno.1994.1004
   Web of Science ®Google Scholar
• Manning K, Fernández-Cañón JM, Montagutelli X, Grompe M. Identification of the mutation in the alkaptonuria mouse model. Mutations in brief no. 216. Online. Hum Mutat. 1999;13(2):171. doi:10.1002/(SICI)1098-1004(1999)13:2<171::AID-HUMU15>3.0.CO;2-W
   Google Scholar
• Schmidt SR, Gehrig A, Koehler MR, Schmid M, Muller CR, Kress W. Cloning of the homogentisate 1,2-dioxygenase gene, the key enzyme of alkaptonuria in mouse. Mamm Genome. 1997;8(3):168–171. doi:10.1007/s003359900383
   Web of Science ®Google Scholar
• Taylor AM, Preston AJ, Paulk NK, et al. Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition. Osteoarthritis Cartilage. 2012;20(8):880–886. doi:10.1016/j.joca.2012.04.013
   PubMed Web of Science ®Google Scholar
• Preston AJ, Keenan CM, Sutherland H, et al. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone. Ann Rheum Dis. 2014;73(1):284–289. doi:10.1136/annrheumdis-2012-202878
   PubMed Web of Science ®Google Scholar
• Keenan CM, Preston AJ, Sutherland H, et al. Nitisinone arrests but does not reverse ochronosis in Alkaptonuric mice. JIMD Rep. 2015;24:45–50.
   PubMedGoogle Scholar
• Ranganath LR, Norman BP, Gallagher JA. Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the disease-A review. J Inherit Metab Dis. 2019;42(5):776–792. doi:10.1002/jimd.v42.5
   PubMed Web of Science ®Google Scholar
• Helliwell TR, Gallagher JA, Ranganath L. Alkaptonuria–a review of surgical and autopsy pathology. Histopathology. 2008;53(5):503–512. doi:10.1111/j.1365-2559.2008.03000.x
   PubMed Web of Science ®Google Scholar
• Ranganath LR, Milan AM, Hughes AT, et al. Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria. JIMD. 2019. doi:10.1002/jimd.12181
   Google Scholar
• Introne WJ, Phornphutkul C, Bernardini I, McLaughlin K, Fitzpatrick D, Gahl WA. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation. Mol Genet Metab. 2002;77(1–2):136–142. doi:10.1016/S1096-7192(02)00121-X
   Web of Science ®Google Scholar
• Taylor AM, Boyde A, Wilson PJ, et al. The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuria. Arthritis Rheum. 2011;63(12):3887–3896. doi:10.1002/art.30606
   PubMed Web of Science ®Google Scholar
• Taylor AM, Wlodarski B, Prior IA, et al. Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology (Oxford). 2010;49(7):1412–1414. doi:10.1093/rheumatology/keq027
   Web of Science ®Google Scholar
• Gallagher JA, Dillon JP, Sireau N, Timmis O, Ranganath LR. Alkaptonuria: an example of a “fundamental disease”–A rare disease with important lessons for more common disorders. Semin Cell Dev Biol. 2016;52:53–57. doi:10.1016/j.semcdb.2016.02.020
   Web of Science ®Google Scholar
• Taylor AM, Hsueh MF, Ranganath LR, et al. Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing. Rheumatology (Oxford). 2017;56(1):156–164. doi:10.1093/rheumatology/kew355
   PubMed Web of Science ®Google Scholar
• Gallagher JA, Taylor AM, Boyde A, Jarvis JC, Ranganath LR. Recent advances in understanding the pathogenesis of ochronosis. Reumatologia. 2012;50(4):316–323.
   Google Scholar
• Millucci L, Braconi D, Bernardini G, et al. Amyloidosis in alkaptonuria. J Inherit Metab Dis. 2015;38(5):797–805. doi:10.1007/s10545-015-9842-8
   Web of Science ®Google Scholar
• Millucci L, Spreafico A, Tinti L, et al. Alkaptonuria is a novel human secondary amyloidogenic disease. Biochim Biophys Acta. 2012;1822(11):1682–1691. doi:10.1016/j.bbadis.2012.07.011
   PubMed Web of Science ®Google Scholar
• Brunetti G, Tummolo A, D’Amato G, et al. Mechanisms of Enhanced Osteoclastogenesis in Alkaptonuria. Am J Pathol. 2018;188(4):1059–1068. doi:10.1016/j.ajpath.2017.12.008
   Web of Science ®Google Scholar
• Bernardini G, Leone G, Millucci L, et al. Homogentisic acid induces morphological and mechanical aberration of ochronotic cartilage in alkaptonuria. J Cell Physiol. 2019;234(5):6696–6708. doi:10.1002/jcp.27416
   Web of Science ®Google Scholar
• Millucci L, Bernardini G, Spreafico A, et al. Histological and ultrastructural characterization of Alkaptonuric tissues. Calcif Tissue Int. 2017;101(1):50–64. doi:10.1007/s00223-017-0260-9
   Web of Science ®Google Scholar
• Taylor AM, Boyde A, Davidson JS, Jarvis JC, Ranganath LR, Gallagher JA. Identification of trabecular excrescences, novel microanatomical structures, present in bone in osteoarthropathies. Eur Cell Mater. 2012;23:300–308; discussion 308–309. doi:10.22203/eCM.v023a23
   Web of Science ®Google Scholar